...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Korean medical science >Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
【24h】

Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.

机译：利妥昔单抗-CHOP治疗弥漫性大B细胞淋巴瘤患者中性粒细胞减少的模式和发热性中性粒细胞减少的危险因素。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Febrile neutropenia (FN) is the major toxicity of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen in the treatment of diffuse large B-cell lymphoma (DLBCL). The prediction of neutropenia and FN is mandatory to continue the planned R-CHOP therapy resulting in successful anti-cancer treatment. The clinical features and patterns of neutropenia and FN from 181 DLBCL patients treated with R-CHOP were analyzed retrospectively. Sixty percent (60.2%) of patients experienced at least one episode of grade 4 neutropenia. Among them, 42.2% of episodes progressed to FN. Forty-eight percent (48.8%) of patients with FN was experienced their first FN during the first cycle of R-CHOP. All those patients never experienced FN again during the rest cycles of R-CHOP. Female, higher stage, international prognostic index (IPI), age ≥65 yr, comorbidities, bone marrow involvement, and baseline serum albumin ≤3.5 mg/dL were significant risk factors for FN by univariate analysis. Among these variables, comorbidities (P=0.009), bone marrow involvement (P=0.006), and female gender (P=0.024) were independent risk factors for FN based on multivariate analysis. On observing the patterns of neutropenia and FN, primary prophylaxis of granulocyte colony-stimulating factor (G-CSF) and antibiotics should be considered particularly in female patients, patients with comorbidities, or when there is bone marrow involvement of disease.
机译：发热性中性粒细胞减少症（FN）是利妥昔单抗加环磷酰胺，阿霉素，长春新碱和泼尼松（R-CHOP）方案治疗弥漫性大B细胞淋巴瘤（DLBCL）的主要毒性。中性粒细胞减少和FN的预测对于继续计划的R-CHOP治疗是成功的，因此必须成功进行抗癌治疗。回顾性分析了181例接受R-CHOP治疗的DLBCL患者中性粒细胞减少和FN的临床特征和特征。 60％（60.2％）的患者经历了至少1次4级中性粒细胞减少症。其中，有42.2％的情节发展为FN。 FN患者中有48％（48.8％）在R-CHOP的第一个周期经历了第一次FN。所有这些患者在R-CHOP的其余周期中再也没有经历过FN。通过单因素分析，女性，更高阶段，国际预后指数（IPI），年龄≥65岁，合并症，骨髓受累以及基线血清白蛋白≤3.5mg / dL是FN的重要危险因素。在这些变量中，合并症（P = 0.009），骨髓受累（P = 0.006）和女性（P = 0.024）是基于多变量分析得出的FN的独立危险因素。在观察中性粒细胞减少和FN的模式时，应特别考虑在女性患者，合并症患者或患有骨髓疾病的患者中预防粒细胞集落刺激因子（G-CSF）和抗生素的一级预防。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号